PhaseRx Inc
PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder program… Read more
PhaseRx Inc (PZRXQ) - Total Assets
Latest total assets as of September 2017: $6.04 Million USD
Based on the latest financial reports, PhaseRx Inc (PZRXQ) holds total assets worth $6.04 Million USD as of September 2017.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
PhaseRx Inc - Total Assets Trend (2014–2016)
This chart illustrates how PhaseRx Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
PhaseRx Inc - Asset Composition Analysis
Current Asset Composition (December 2016)
PhaseRx Inc's total assets of $6.04 Million consist of 98.4% current assets and 1.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 60.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $271.00K | 1.7% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2016)
This chart illustrates how PhaseRx Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PhaseRx Inc's current assets represent 98.4% of total assets in 2016, an increase from 83.0% in 2014.
- Cash Position: Cash and equivalents constituted 60.7% of total assets in 2016, down from 76.4% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is property, plant & equipment at 1.7% of total assets.
PhaseRx Inc Competitors by Total Assets
Key competitors of PhaseRx Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
PhaseRx Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - PhaseRx Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - PhaseRx Inc is currently not profitable relative to its asset base.
PhaseRx Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.14 | 15.16 | 0.15 |
| Quick Ratio | 2.14 | 15.16 | 0.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.10 Million | $ 17.81 Million | $ -20.25 Million |
PhaseRx Inc - Advanced Valuation Insights
This section examines the relationship between PhaseRx Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.25 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 320.2% |
| Total Assets | $16.45 Million |
| Market Capitalization | $1.02K USD |
Valuation Analysis
Below Book Valuation: The market values PhaseRx Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: PhaseRx Inc's assets grew by 320.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for PhaseRx Inc (2014–2016)
The table below shows the annual total assets of PhaseRx Inc from 2014 to 2016.
| Year | Total Assets | Change |
|---|---|---|
| 2016-12-31 | $16.45 Million | +320.24% |
| 2015-12-31 | $3.91 Million | +47.20% |
| 2014-12-31 | $2.66 Million | -- |